Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
about
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjectsImpaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiencyApplications of CYP450 testing in the clinical settingEffects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazidePharmacogenetic studies update in type 2 diabetes mellitusCYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drugA Common Susceptibility Gene for Type 2 Diabetes Is Associated with Drug Response to a DPP-4 Inhibitor: Pharmacogenomic Cohort in Okinawa JapanPharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of GujaratLoss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testingSulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Pharmacogenetics of Anti-Diabetes Drugs.Implications of pharmacogenetics for individualizing drug treatment and for study design.Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.Pharmacogenetics of glucose-lowering drug treatment: a systematic review.CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patientsPharmacogenetics of oral antidiabetic drugs.CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob micePossible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion among non-diabetic family members of type 2 diabetic patients.Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
P2860
Q24564755-C5D6D2A6-A047-46B7-8DAA-178C774290B9Q24609157-83711F68-1A94-46F6-8E40-A5DAC5DAB3CCQ24621760-0FCED172-8954-4697-88D4-959266A36E39Q24651117-0E5BFA73-F00C-4772-8067-49FA62CAD193Q26739350-699ACDE8-D16E-421A-B69C-236B22B1BA80Q28544111-E92DDA20-1498-4553-A566-BF63A0B27121Q28551748-730A5FCB-526D-4E1A-A1FF-B5BB8781026DQ30388214-E4EB4560-9066-49E8-9633-B203A95C0CD8Q30571118-A32ACF6F-9DDB-4F9A-B1D5-16384F84A4E9Q31044030-1528EB27-139B-4B98-82F8-D533827E5F31Q31144283-528309DE-83B5-40D2-AA04-4762C4991CA0Q33555327-E3486940-5CE2-4131-9DF8-EDFBFD9E4D66Q33779389-5F41B4E8-53AE-44D8-B90A-9375A4E58BE8Q33813015-76486AE9-56D4-4D2F-8539-BFB866C79C2FQ33993320-89AFCEF5-E68C-4A3C-A7DF-CEBA6B10DDDAQ34181995-3CDEB2A3-52FA-40B2-B866-505C88D6340EQ35102211-8FE33475-C742-4D17-A51C-52EFF19C47F1Q35594567-70EFE81B-7803-4966-A375-21ED8426A5DBQ35753607-DBA80EC1-2419-47AD-9456-168F7A883907Q35826971-BE1CB591-3304-4655-AEEC-DD450DED4188Q35876954-C3B5D00C-4566-4BF1-914C-EE4C15BFCF00Q36702588-9F504604-2473-4167-83EB-9479FB1F6D13Q36982648-ECA43110-B59F-4017-9700-073518DA231BQ37227417-45C81214-B31F-4BD4-B82A-62740B9A51D8Q37353476-C504930A-C326-4248-81BF-2636E644A5D5Q38059889-42A71F5C-CEC9-464F-A37B-C2256263F758Q38110432-C226A4F3-A319-4DA3-91A9-B155C2368F93Q38270699-2FDD3EEF-42AE-450C-B727-A6C36562D233Q38349437-7094AB10-0352-4826-BB64-1E00481A57BCQ39154772-C786777D-5D6E-4279-882A-5F8C3F5D5C23Q41737190-E10425AC-064E-47C5-BFB4-9272966C62E2Q42284131-6A410D5F-E121-444E-979F-9A19C3F0FB30Q42758783-3442C130-AA52-4DED-814D-D0834D826A27Q42788961-F897AD6B-3B03-4F95-889C-3D689CE0B041Q43248039-990BB13A-832C-46D6-99CD-9A8D0D01B4DDQ43268894-A2D50453-CE1C-4DE1-B36F-64B3834B8700Q43419612-47BDC51A-9499-417B-8176-3A556FF54099Q44273797-8E8D834B-D874-4905-A1B6-A5171267B103Q44405606-665A3C7B-3B00-4056-9F74-C553EA90089BQ44487379-0D4ECC85-FF67-4E46-8DB7-8B3681C185CC
P2860
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Impact of CYP2C9 and CYP2C19 p ...... esponse in healthy volunteers.
@en
Impact of CYP2C9 and CYP2C19 p ...... esponse in healthy volunteers.
@nl
type
label
Impact of CYP2C9 and CYP2C19 p ...... esponse in healthy volunteers.
@en
Impact of CYP2C9 and CYP2C19 p ...... esponse in healthy volunteers.
@nl
prefLabel
Impact of CYP2C9 and CYP2C19 p ...... esponse in healthy volunteers.
@en
Impact of CYP2C9 and CYP2C19 p ...... esponse in healthy volunteers.
@nl
P2093
P1476
Impact of CYP2C9 and CYP2C19 p ...... esponse in healthy volunteers.
@en
P2093
Christian Meisel
Ingolf Meineke
Ivor Roots
Julia Kirchheiner
Jürgen Brockmöller
Steffen Bauer
Verena Prang
Wolfgang Rohde
P304
P356
10.1097/00008571-200203000-00004
P577
2002-03-01T00:00:00Z